tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB) and NeuBase Therapeutics (NBSE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Solid Biosciences (SLDBResearch Report) and NeuBase Therapeutics (NBSEResearch Report) with bullish sentiments.

Solid Biosciences (SLDB)

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Solid Biosciences on August 11 and set a price target of $6.00. The company’s shares closed last Friday at $0.80, close to its 52-week low of $0.42.

According to TipRanks.com, Livshits is a 5-star analyst with an average return of 28.5% and a 45.2% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

Solid Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.

See the top stocks recommended by analysts >>

NeuBase Therapeutics (NBSE)

Chardan Capital analyst Keay Nakae maintained a Buy rating on NeuBase Therapeutics on August 11 and set a price target of $7.00. The company’s shares closed last Friday at $1.14, close to its 52-week low of $0.77.

According to TipRanks.com, Nakae is a 4-star analyst with an average return of 7.8% and a 41.8% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Better Therapeutics, Inc., Arrowhead Pharmaceuticals, and Emergent Biosolutions.

Currently, the analyst consensus on NeuBase Therapeutics is a Moderate Buy with an average price target of $8.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SLDB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More